[PDF][PDF] Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
QC Ryan, D Headlee, M Acharya… - Journal of Clinical …, 2005 - researchgate.net
QC Ryan, D Headlee, M Acharya, A Sparreboom, JB Trepel, J Ye, WD Figg, K Hwang…
Journal of Clinical Oncology, 2005•researchgate.netPhase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients
With Advanced and Refractory Solid Tum Page 1 Phase I and Pharmacokinetic Study of MS-275,
a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or
Lymphoma Qin C. Ryan, Donna Headlee, Milin Acharya, Alex Sparreboom, Jane B. Trepel,
Joseph Ye, William D. Figg, Kyunghwa Hwang, Eun Joo Chung, Anthony Murgo, Giovanni
Melillo, Yusri Elsayed, Manish Monga, Mikhail Kalnitskiy, James Zwiebel, and Edward A …
With Advanced and Refractory Solid Tum Page 1 Phase I and Pharmacokinetic Study of MS-275,
a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or
Lymphoma Qin C. Ryan, Donna Headlee, Milin Acharya, Alex Sparreboom, Jane B. Trepel,
Joseph Ye, William D. Figg, Kyunghwa Hwang, Eun Joo Chung, Anthony Murgo, Giovanni
Melillo, Yusri Elsayed, Manish Monga, Mikhail Kalnitskiy, James Zwiebel, and Edward A …
Purpose
The objective of this study was to define the maximum-tolerated dose (MTD), the recommended phase II dose, the dose-limiting toxicity, and determine the pharmacokinetic (PK) and pharmacodynamic profiles of MS-275.
researchgate.net